Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.

Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.

BACKGROUND: Recently, the type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling and imaging studies of a murin...

Full description

Bibliographic Details
Main Authors: Kitchener D Wilson, Zongjin Li, Roger Wagner, Patrick Yue, Phillip Tsao, Gergana Nestorova, Mei Huang, David L Hirschberg, Paul G Yock, Thomas Quertermous, Joseph C Wu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2481284?pdf=render

Internet

http://europepmc.org/articles/PMC2481284?pdf=render

Similar Items